Portage Biotech : NOTICE TO READER OF CONDENSED CONSOLIDATED

NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS


The condensed consolidated interim financial statements of Portage Biotech Inc. are comprised of the...

Related Keywords

Delaware , United States , France , Canada , British Virgin Islands , Lincoln Park , Paris , France General , Road Town , British Virgin Islands General , United Kingdom , Luxembourg , Westport , Newfoundland , Canadian , British , Mark Simon , Stimunity Sa , Ian Walters , James Mellon , Linda Kozick , Oncomer Saugatuck , Allan Shaw , Cantor Fitzgerald Co , Details Of The Company , Party Transactions , Portage Merger Subi Inc , Saugatuck Therapeutics Ltd , Nasdaq , Master Services Agreement , Share Exchange Agreement , Intensity Holdings Limited , Ox Share Exchange On , Labcorp Drug Development Inc , Intensity Therapeutics Inc , Impetis Biosciences , Nekonal Oncology Limited , Services Agreements , Portage Development Services Inc , International Financial Reporting Interpretations Committee , Salvarx Group , Fortrea Inc , International Accounting Standards Board , Ox Share Exchange Agreement , Contract Research Organization , Discussion Group Public Meeting , Portage Biotech Inc , Canadian Securities Exchange , Owners Of The Company , Audit Committee , Company On , While The Company , Investment In Public Company , Salvarx Limited , Company Or Portage , Compensation Committee , Service Agreement , Tarus Therapeutics , Exchange Commission , Parexel International , Lincoln Park Capital Fund , Service Agreements , Portage Merger Sub , Company The Salvarx Acquisition , Company Nasdaq , Investments In Associates , Services Agreement , Share Exchange Agreement The , Saugatuck Rx , Hox Therapeutics Ltd , Fast Forward Innovations Limited , International Financial Reporting Standards , Tarus Therapeutics Inc , Cantor Fitzgerald , Rift Biotherapeutics Inc , Portage Biotech , International Financial Reporting , Chief Executive Officer , Consolidated Interim Statements , Contingent Liabilities , Months Ended June , Three Months Ended June , Committed Purchase Agreement , Condensed Consolidated Interim Financial , Clarence Thomas Building , Portage Development Services , Nasdaq Capital Market , Salvarx Acquisition , Intensity Therapeutics , Saugatuck Therapeutics , Exchange Agreement , Financial Reporting , International Financial Reporting Interpretations , British Virgin , Stimunity Convertible Note , Significant New , Time Adoption , Accounting Standards , Its Associate , Financial Statements , Joint Ventures , Rights Held , Shareholder Agreement , Maturity Date , Common Shares , Minimum Raise , Convertible Note , Merger Agreement , License Agreement , Impetis Biosciences Limited , Call Option , Tarus License Agreement , Adenosine Compounds , Tarus Therapeutic , Multi Period Excess Earnings Method , Replacement Cost Method , Registration Statement , Controlled Equity Offering Sales Agreement , Sales Agreement , Securities Act , Purchase Agreement , Purchase Shares , Committed Purchase , Depository Trust Company , Nasdaq See Note , Option Plan , Incentive Plan , Stock Options , Restricted Stock , Subsidiary Plan , Work Order , Stimunity Convertible , Signing Date , Registration Rights Agreement , Tarus Merger Agreement , Group Public Meeting , Financial Liabilities , Equity Instruments , Per Share Earnout Price , Earnout Shares , Good Reason , Just Cause , Severance Benefits , Termination Date , Accrued Obligations , Control Severance Benefits , Executive Services Agreements , Executive Services Agreement , Base Salary , Nominating Committee , Note Receivable , Public Company , Upon Intensity , Equity Issuable , Purchase Price Payable , Income Approach , Liquidity Risk , Foreign Currency , Markets ,